Devyser Diagnostics (DVYSR) Q3 2025 earnings summary

Executive summary

• Q3 2025 revenue reached SEK 56.4 million, up 16% year-over-year, with gross margin at 75% and EBIT at SEK 1.3 million, marking a return to profitability.

• Year-to-date sales totaled SEK 179 million, a 17% increase from last year, with gross margin at 81% and EBIT at minus SEK 8 million.

• Cash position at quarter-end was SEK 85 million, with no debt.

• New CEO Jan Wahlström appointed in August, bringing industry experience.

• Focus remains on profitability, efficiency, and leveraging new product launches.

Financial highlights

• Q3 sales grew to SEK 56.4 million from SEK 48.7 million, a 15.7% increase year-over-year.

• Gross margin for Q3 was 75%; year-to-date gross margin was 81%.

• EBIT turned positive at SEK 1.3 million for Q3, second consecutive positive quarter.

• Cash flow for Q3: minus SEK 15.2 million, mainly due to capitalized R&D; operating cash flow only minus SEK 0.5 million.

• Year-to-date sales: SEK 179 million, up 17% year-over-year.

Outlook and guidance

• H2 expected to be stronger than H1, with Q4 distributor sales anticipated to rebound after a slow Q3.

• No changes to long-term financial targets; aiming for 30% growth and 20% EBIT margin.

• Confident in reaching cash flow positive status in the foreseeable future.

• Ongoing focus on cost control and efficiency improvements.

• Orders from Thermo Fisher expected to strengthen in Q4, following seasonal patterns.